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OBJECTIVES 
Existing evidence comparing the outcomes of coronary artery bypass graft (CABG) surgery 
versus percutaneous coronary intervention (PCI) in patients with poor left ventricular 
function (LVF) is sparse and flawed. This is largely due to patients with poor LVF being 
underrepresented in major research trials and the outdated nature of some studies that do not 
consider drug-eluting stent PCI. 
METHODS 
Following strict inclusion criteria, 717 patients who underwent revascularization by CABG or 
PCI between 2002 and 2015 were enrolled. All patients had poor LVF (defined by ejection 
fraction <30%). By employing a propensity score analysis, 134 suitable matches (67 CABG 
and 67 PCI) were identified. Several outcomes were evaluated, in the matched population, 
using data extracted from national registry databases. 
RESULTS 
CABG patients required a longer length of hospital stay post-revascularization compared to 
PCI in the propensity-matched population, 7 days (lower–upper quartile; 6–12) and 2 days 
(lower–upper quartile; 1–6), respectively (Mood’s median test, P = 0.001). Stratified Cox-
regression proportional-hazards analysis of the propensity-matched population found that PCI 
patients experienced a higher adjusted 8-year mortality rate (hazard ratio 3.291, 95% 
confidence interval 1.776–6.101; P < 0.001). This trend was consistent amongst urgent cases 
of revascularization: patients with 3 or more vessels with coronary artery disease and patients 
where complete revascularization was achieved. Although sub-analyses found no difference 
between survival distributions of on-pump versus off-pump CABG (log-rank P = 0.726), both 
modes of CABG were superior to PCI (stratified log-rank P = 0.002). 
CONCLUSIONS 
Despite a longer length of hospital stay, patients with impaired LVF requiring intervention 
for coronary artery disease experienced a greater post-procedural survival benefit if they 
received CABG compared to PCI. We have demonstrated this at 30 days, 90 days, 1 year, 
3 years, 5 years and 8 years following revascularization. At present, CABG remains a 
superior revascularization modality to PCI in patients with poor LVF.  
INTRODUCTION 
In recent decades, the rate of death from coronary artery disease (CAD) has been crippled by 
the advent of 2 efficacious and widely available treatments: Coronary artery bypass graft 
(CABG) surgery and percutaneous coronary intervention (PCI) [1]. In the absence of 
conclusive evidence from randomized controlled trials (RCTs), the 2 revascularization 
strategies have naturally been the subject of a contentious debate to determine which 
modality is superior in patients with poor left ventricular function (LVF). 
The weak evidence base is reflected in current guidelines. The most recent 2014 European 
Society of Cardiology and European Association for Cardio-Thoracic Surgery (ESC/EACTS) 
guidelines summarize the recommended approach for revascularization in patients with poor 
LVF [2]. CABG is a class I recommendation, supported by level B and C standard of 
evidence. This recommendation stems from the results of the STICH trial where Velazquez et 
al. [3] found that patients who received CABG with medical therapy had significantly lower 
rates of death, from cardiovascular causes, compared to lone medical therapy. The success of 
CABG in heart failure has been emulated in a number of studies [4–6]. By contrast, there is a 
paucity of information regarding the role of PCI in patients with poor LVF. The ESC/EACTS 
2014 guidelines state that ‘PCI may be considered …’ under the guise of a class IIb 
recommendation with level C evidence. Of the evidence that does exist, poor LVF is 
generally correlated with higher post-PCI mortality [7–9]. Furthermore, the guidelines do not 
mention any study that directly compares PCI with CABG in patients with poor LVF. This is 
disappointing and reiterates the need for further investigation into this topic. 
Under current clinical practice, patients with poor LVF may not be receiving the best 
treatment. Consequently, they may be at higher risk of post-procedural complications, 
including mortality. This study aims to be the first clinical quality assessment in the UK to 
compare and evaluate the outcomes of PCI and CABG in patients with poor LVF. By 
employing a propensity score matching technique, we aim to minimize the bias that would 
otherwise undermine the value of such a retrospective study. 
METHODS 
Patient selection 
Patients were selected from the British Cardiovascular Intervention Society (BCIS) and 
Society for Cardiothoracic Surgery (SCTS) registries. Validated patient data were collected 
with the Centricity Carddas (GE Healthcare, Chicago, IL, USA) and Cardiac PATS (Dendrite 
Clinical Systems Ltd, Henley-on-Thames, UK) and submitted to the BCIS and SCTS, 
respectively. The data were entered by the primary operator in the database. Completeness 
and accuracy of the data were validated in-house by the data manager before submission to 
the registries. For the purpose of this study, the data were then extracted by the data manager, 
who is responsible for submission. All patients who received CABG or PCI at the Bristol 
Royal Infirmary (BRI) between April 2002 and April 2015 and had poor LVF were included. 
Poor LVF was defined as a left ventricular ejection fraction (LVEF) of 30% or less and was 
based on the pre-operative transthoracic echocardiogram. These patients are discussed at our 
Heart Team multi-disciplinary weekly meetings to achieve a consensus whether to proceed 
with CABG or PCI. Magnetic resonance imaging to assess myocardial viability is performed 
before proceeding with any intervention. We excluded redo CABG procedures (i.e. CABG in 
patients who had prior CABG operations) and CABG procedures that were performed in 
conjunction with valve or major aortic surgery in the same operation. We excluded any 
emergency procedures (procedure performed without further delay; only elective and urgent 
procedures, during the same admission, were included), patients requiring primary PCI for 
ST elevation myocardial infarction (MI), haemodynamically unstable patients and patients in 
cardiogenic shock. 
Propensity score matching 
Seventeen independent variables (Table 1), describing various characteristics of the patient 
and the presenting lesion(s), were appropriately chosen and incorporated into a logistic 
regression model in order to generate a propensity score for each patient [10]. The propensity 
score, ranging from 0 to 1, describes a patient’s likelihood of receiving CABG (1), relative to 
PCI (0). To avoid large standardized differences, caliper widths defined as 0.1 of the standard 
deviation of the logit of the propensity score were employed to achieve more identical pairs. 
A nearest neighbour, without replacement, matching protocol was employed to match CABG 
patients with PCI patients. Frequencies of the 17 independent variables are presented in 
Table 1. Standardized difference of means was calculated for both continuous and categorical 
variables in order to ensure that the frequency of a variable was equally balanced between the 
CABG and PCI arms of the matched population. We refitted the propensity score model with 
interaction terms in order to reduce the potential bias as much as possible where imbalance 
was found. 
Table 1: 
Frequencies of patient and lesion characteristics in the original and propensity-matched 
population 
Variables  
Original population 
 
  
Propensity-matched population 
 
  
  
PCI 
(n = 219
)  
CABG 
(n = 498
)  
Standardiz
ed 
difference  
PCI 
(n = 67
)  
CABG 
(n = 67
)  
Standardiz
ed 
difference  
Age (years)  
 Mean (SD)  
72.1 
(11.04)  
65.2 
(12.93)  0.557  
70.7 
(11.21)
  
70.8 
(9.48)  0.102  
 Median  74.0  68.0    74.0  73.5    
Height (cm)  
 Mean (SD)  
171.1 
(9.08)  
171.5 
(9.05)  0.044  
171.9 
(9.65)  
171.4 
(7.90)  0.054  
Weight (kg)  
 Mean (SD)  
80.1 
(15.04)  
82.3 
(15.52)  0.143  
84.8 
(13.96)
  
81.4 
(14.51)
  0.233  
BMI (kg/m2)  
 Mean (SD)  
27.3 
(4.64)  
24.2 
(10.90)  0.328  
28.7 
(4.76)  
27.7 
(4.62)  0.213  
Gender (%)  
Variables  
Original population 
 
  
Propensity-matched population 
 
  
  
PCI 
(n = 219
)  
CABG 
(n = 498
)  
Standardiz
ed 
difference  
PCI 
(n = 67
)  
CABG 
(n = 67
)  
Standardiz
ed 
difference  
 Male  
180 
(82.2)  
428 
(85.9)  0.105  
58 
(86.6)  
59 
(88.1)  0.045  
 Female  
39 
(17.8)  
70 
(14.1)    
9 
(13.4)  
8 
(11.9)    
Smoking status (%)  
 Never 
smoked  
46 
(21.0)  
109 
(21.9)  0.388  
13 
(19.4)  
15 
(22.4)  0.043  
 Ex-smoker  
93 
(42.5)  
294 
(59.0)    
37 
(55.2)  
31 
(46.3)    
 Current 
smoker  
58 
(26.5)  
95 
(19.1)    
17 
(25.4)  
21 
(31.3)    
Diabetic (%)  
66 
(30.1)  
164 
(32.9)  0.060  
21 
(31.3)  
20 
(29.9)  0.032  
Hypertension 
(%)  
169 
(77.2)  
360 
(72.3)  0.012  
54 
(80.6)  
56 
(83.6)  0.078  
Neurological 
disease (%)a  
14 
(6.4)  
58 
(11.6)  0.174  6 (9.0)  6 (9.0)  0.000  
Peripheral 
vascular 
disease (%)  
28 
(12.8)  
78 
(15.7)  0.082  
11 
(16.4)  
9 
(13.4)  0.084  
Renal disease 
(%)b  
16 
(7.3)  
12 
(2.4)  0.255  4 (6.0)  3 (4.5)  0.067  
Previous MI 
(%)  
122 
(55.7)  
417 
(83.7)  0.679  
51 
(76.1)  
53 
(79.1)  0.072  
Variables  
Original population 
 
  
Propensity-matched population 
 
  
  
PCI 
(n = 219
)  
CABG 
(n = 498
)  
Standardiz
ed 
difference  
PCI 
(n = 67
)  
CABG 
(n = 67
)  
Standardiz
ed 
difference  
Previous PCI 
(%)  
53 
(24.2)  
34 
(6.8)  0.550  
12 
(17.9)  
13 
(19.4)  0.038  
Procedure urgency (%)  
 Elective  
62 
(28.3)  
178 
(35.7)  0.155  
22 
(32.8)  
19 
(28.4)  0.097  
 Urgent  
156 
(71.2)  
320 
(64.3)    
45 
(67.2)  
48 
(71.6)    
Extent of CAD (%)c  
 Single 
vessel  
55 
(25.1)  
14 
(2.8)  0.954  
8 
(11.9)  5 (7.5)  0.112  
 Double 
vessel  
74 
(33.8)  
104 
(20.9)    
19 
(28.4)  
20 
(29.9)    
 Triple 
vessel  
89 
(40.6)  
380 
(76.3)    
40 
(59.7)  
42 
(62.7)    
LMS disease 
(%)d  
38 
(17.4)  
147 
(29.5)  0.279  
20 
(29.9)  
23 
(34.4)  0.096  
Complete 
revascularizati
on (%)e  
124 
(56.6)  
425 
(85.3)  0.713  
48 
(71.6)  
48 
(71.6)  0.000  
a 
History of neurological disease = if patient has suffered 1 or more cerebrovascular event i.e. 
transient ischaemic attack or stroke. 
b 
History of renal disease = if the patient’s pre-intervention renal function was abnormal i.e. 
plasma creatinine >200 µmol/l. 
c 
Extent of CAD = number of coronary arteries with ≥50% diameter stenosis. 
d 
LMS disease = LMS coronary artery with ≥50% diameter stenosis. 
e 
Complete revascularization = complete revascularization was achieved if: (i) (for CABG) 
anastomoses distal to lesion(s) were made in all arteries with CAD; (ii) (for PCI) if 
intervention, by angioplasty or stent, was successfully achieved in all arteries with CAD. 
BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; 
LMS: left main stem; MI: myocardial infarction; PCI: percutaneous coronary intervention; 
SD: standard deviation. 
Statistical analyses and outcomes 
Using the data from the BCIS and SCTS registries, we observed 2 short-term outcomes: Life 
status of the patient at discharge and length of hospital stay following revascularization. The 
former is compared between the PCI and CABG groups by the Pearson’s χ2 test. The latter is 
assessed by the Mood’s median test to compare medians in the propensity-matched 
population. The principal, long-term outcome observed was all-cause mortality, measured at 
specific time points after the procedure was performed (30 days, 90 days, 1 year, 3 years, 
5 years, and 8 years). These data were extracted from the BCIS and SCTS registries and 
supplemented by BRI databases. Date of final follow-up was 9 April 2018 at which point 0 
patients were lost to follow-up. An 8-year survival analysis was performed using the Kaplan–
Meier estimator model on the propensity-matched population. All Kaplan–Meier survival 
distributions were compared using the Mantel–Cox log-rank test stratified on the matched 
pairs to account for the matched nature of the data. Multivariable Cox proportional-hazards 
regression model, also stratified on the matched pairs, was subsequently applied to the 
matched population to identify any independent predictor of mortality. Covariates were 
included via a stepwise regression using a probability for stepwise entry of 0.05. 
Proportional-hazards assumption of the Cox regression model was tested graphically by 
means of log-minus-log plots of variables included in the regression model. We also explored 
differences in 8-year survival distributions between the on-pump and off-pump CABG 
procedures. Sub-analyses were conducted in order to determine whether the survival trends 
were consistent amongst subgroups. These subgroups include (i) procedure urgency, (ii) left 
main stem (LMS) disease, (iii) extent of CAD and (iv) completeness of revascularization. All 
statistics presented in this study were produced using IBM SPSS Statistics 24 (IBM 
Corporation, Armonk, NY, USA). All statistics reported apply to the propensity-matched 
population unless otherwise stated. 
RESULTS 
Our final dataset consisted of 717 patients, of whom 219 underwent PCI and 498 underwent 
CABG. Propensity score matching identified 134 suitable matches: 67 CABG and 67 PCI. 
Standardized differences and distribution of propensity scores showed extreme 
incomparability between the 2 treatment groups in the pre-matched population. Pre- and post-
matched plots of the propensity score distributions are presented to show comparability of 
groups after matching (Fig. 1A and B). 
Figure 1: 
Mirror histogram showing distribution of propensity scores in (A) the pre-matched 
population and (B) the post-matched population. CABG: coronary artery bypass graft; PCI: 
percutaneous coronary intervention. 
 
The median length of follow-up was 5 years, and maximum length of follow-up was 15 years. 
Within the matched population, 58 deaths occurred during the 8-year follow-up period (37 
PCI, 21 CABG). Of the PCI procedures, 71.6% used drug-eluting stent (DES). The remainder 
of PCI involved bare metal stents or balloon angioplasty only. Of the 67 CABG patients, 
47.8% and 49.2% underwent the on- and off-pump procedures, respectively. The nature of 
the procedure is unknown for the remaining 3.0%. Extent of CAD and LMS disease was 
defined by the number of vessels, or LMS, with ≥50% diameter stenosis. Extent of CAD was 
divided into 3 categories: 9.7%, 29.1% and 61.2% of patients had single, double or 3 or more 
vessels with CAD, respectively (Table 1). Of the matched population, 32.1% presented with 
LMS disease: 20 PCI and 23 CABG. Completeness of revascularization was achieved in a 
majority of patients, 71.6% for PCI and 71.6% for CABG. 
Short-term outcomes 
The Mood’s median test found that CABG patients had a longer length of hospital stay 
compared to PCI patients, 7 days (lower–upper quartile; 6–12) and 2 days (lower–upper 
quartile; 1–6), respectively (P = 0.001) (Fig. 2). In-hospital mortality was 10.4% for PCI and 
4.5% for CABG patients. The Pearson’s χ2 test found this difference insignificant (P = 0.189). 
Figure 2: 
 
Length of hospital stay following revascularization by CABG or PCI. CABG: coronary artery 
bypass graft; PCI: percutaneous coronary intervention. 
 
Long-term outcomes 
The 8-year cumulative survival rate was 33.5 ± 8.0% and 66.9 ± 6.0% for PCI and CABG, 
respectively. The 30-day, 90-day, 1-year, 3-year and 5-year cumulative survival rates were 
also calculated (Table 2). The difference in survival distributions was consistent throughout 
the 8-year follow-up period (stratified log-rank P < 0.001) (Fig. 3A). 
Table 2: 
Kaplan–Meier survival table: PCI versus CABG 
Treatment  
Follow-up interval 
post-
revascularization  
Number 
alive at 
beginning of 
interval  
Number of 
cumulative 
deaths  
Cumulative 
survival % 
(± SE)  
PCI  0 days  67  2  97.0 (2.1)  
  30 days  60  7  89.6 (3.7)  
  90 days  59  8  88.1 (4.0)  
  1 year  53  14  79.1 (5.0)  
  3 years  43  24  64.2 (5.9)  
  5 years  22  33  48.0 (6.4)  
  8 years  6  37  33.5 (8.0)  
CABG  0 days  67  0  100.0 (0.0)  
  30 days  65  2  97.0 (2.1)  
Treatment  
Follow-up interval 
post-
revascularization  
Number 
alive at 
beginning of 
interval  
Number of 
cumulative 
deaths  
Cumulative 
survival % 
(± SE)  
  90 days  63  4  94.0 (2.9)  
  1 year  60  7  89.6 (3.7)  
  3 years  54  13  80.6 (4.8)  
  5 years  49  15  77.5 (5.1)  
  8 years  36  21  66.9 (6.0)  
ABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; SE: standard 
error. 
Figure 3: 
Eight-year cumulative survival of patients with poor left ventricular function: (A) PCI versus 
CABG and (B) PCI versus off-pump CABG versus on-pump CABG. CABG: coronary artery 
bypass graft; PCI: percutaneous coronary intervention. 
 
Prior to multivariable regression analysis, the 8-year unadjusted hazard rate for PCI was 2.6 
times higher than CABG [hazard ratio (HR) 2.603, 95% confidence interval (CI) 1.500–
4.515; P = 0.001]. All variables listed in Table 1, except weight and height, were included in 
the stratified Cox regression model (Table 3). The adjusted HR described a higher 8-year 
mortality rate in the PCI group than in the CABG group (HR 3.291, 95% CI 1.776–
6.101; P < 0.001). Poor preprocedural renal function (creatinine >200 µmol/l), hypertension 
and previous MI were identified as significant independent predictors of 8-year mortality 
(P < 0.001, P = 0.002, P = 0.012, respectively). Age and procedural urgency appeared to 
predict 8-year mortality although the results were not significant (P = 0.059, P = 0.071). 
Table 3: 
Stratified Cox proportional-hazards regression predictors of 8-year mortality: PCI versus 
CABG 
Variable  
Hazard 
ratio  
95% confidence 
interval  
P-
value  
Unadjusted  
 Treatment (PCI)  2.603  1.500–4.515  0.001  
Adjusteda  
 Treatment (PCI)  3.291  1.776–6.101  <0.001  
 Age (years)  1.029  0.999–1.061  0.059  
 BMI (kg/m2)  1.018  0.938–1.104  0.673  
 Female  1.500  0.682–3.297  0.313  
 Diabetes  1.604  0.804–3.202  0.180  
 Absence of hypertension  0.128  0.035–0.460  0.002  
 Absence of neurological disease  0.804  0.295–2.192  0.671  
 Absence of peripheral vascular 
disease  0.670  0.339–1.324  0.249  
 Absence of renal disease  0.104  0.036–0.302  <0.001  
 Previous MI  2.614  1.235–5.533  0.012  
 Previous PCI  0.829  0.379–1.807  0.635  
 Procedural urgency  0.555  0.288–1.067  0.078  
 Extent of CAD (single versus 
multi-vessel)  0.557  0.179–1.737  0.314  
 Absence of left main stem disease  0.881  0.472–1.645  0.691  
 Incomplete revascularization  1.488  0.802–2.761  0.207  
a 
All variables listed in Table 1, except weight and height, were included in the Cox regression 
model. 
BMI: body mass index; CABG: coronary artery bypass graft; CAD: coronary artery disease; 
MI: myocardial infarction; PCI: percutaneous coronary intervention. 
The Kaplan–Meier survival analysis of the on-pump versus off-pump CABG found no 
significant difference between survival distributions (log-rank P = 0.726). However, both 
modes of CABG were superior to PCI as summarized in Table 4 and demonstrated in Fig. 3B 
(stratified log-rank P = 0.002) (Table 4) (Fig. 3B). In elective cases, there was no significant 
difference in survival function between patients who received PCI or CABG (P = 0.310). The 
same analysis in urgent cases found that patients who receive PCI had 3 times the hazard of 
dying compared to CABG patients (HR 3.121, 95% CI 1.644–5.924; P = 0.001). Sub-
analyses found no difference in the 8-year mortality rates of CABG and PCI amongst subjects 
presenting with single-vessel CAD. The 8-year mortality rate in the PCI group was almost 
thrice as large as CABG in patients who presented with triple-vessel CAD (HR 2.596, 95% 
CI 1.355–4.974; P = 0.004). In patients without LMS disease, there was a higher 8-year 
mortality rate amongst the PCI group (HR 2.880, 95% CI 1.436–5778; P = 0.003). Although 
this trend seemed to extend to patients with LMS disease, there was no significant difference 
between the survival distribution of PCI and CABG patients (P = 0.081). When complete 
revascularization was achieved, the CABG group experienced a lower 8-year mortality rate 
than patients who underwent PCI (HR 4.279, 95% CI 2.090–8.764; P < 0.001). No difference 
in 8-year mortality rate was observed for procedures with incomplete revascularization. 
Table 4: 
Kaplan–Meier survival table: PCI versus off-pump CABG versus on-pump CABG 
Treatment  
Follow-up interval 
post-
revascularization  
Number 
alive at 
beginning of 
interval  
Number of 
cumulative 
deaths  
Cumulative 
survival % 
(±SE)  
PCI  0 days  67  2  97.0 (2.1)  
  30 days  60  7  89.6 (3.7)  
  90 days  59  8  88.1 (4.0)  
  1 year  53  14  79.1 (5.0)  
  3 years  43  24  64.2 (5.9)  
Treatment  
Follow-up interval 
post-
revascularization  
Number 
alive at 
beginning of 
interval  
Number of 
cumulative 
deaths  
Cumulative 
survival % 
(±SE)  
  5 years  22  33  48.0 (6.4)  
  8 years  6  37  33.5 (8.0)  
Off-pump 
CABG  0 days  33  0  100.0 (0.0)  
  30 days  32  1  97.0 (3.0)  
  90 days  31  2  93.9 (4.2)  
  1 year  29  4  87.9 (5.7)  
  3 years  27  6  81.8 (6.7)  
  5 years  26  7  78.8 (7.1)  
  8 years  22  11  66.7 (8.2)  
On-pump 
CABG  
0 days  32  0  100.0 (0.0)  
30 days  31  1  96.9 (3.1)  
  90 days  30  2  93.8 (4.3)  
  1 year  29  3  90.6 (5.2)  
  3 years  26  6  81.3 (6.9)  
  5 years  25  7  78.1 (7.3)  
  8 years  14  9  68.9 (8.9)  
CABG: coronary artery bypass graft; PCI: percutaneous coronary intervention; SE: standard 
error. 
DISCUSSION 
Best practice is defined by conclusive and reliable evidence. However, in the field of 
revascularization, reliable evidence does not exist for patients with poor LVF as these 
patients are categorically underrepresented in major studies. This is demonstrated by the 
FREEDOM trial. Their sub-analyses found no significant difference between the outcomes of 
PCI and CABG amongst patients with poor LVF. This must be interpreted with caution as 
only 3.3% of PCI patients and 1.7% CABG patients in the trial had poor LVF [11]. Similar 
critiques found that only 2% and 21% of the cohorts enrolled in the SYNTAX and 
AWESOME trials had poor LVF, respectively [12]. Furthermore, the majority of studies that 
investigate poor LVF in revascularization are outdated as they were conducted before DES 
was introduced in interventional cardiology [13, 14]. Thus, the conclusions drawn from these 
studies are less applicable to modern medicine. Until an up-to-date RCT is conducted, this 
study aims to provide the next best level of evidence with an exclusive interest in patients 
with poor LVF. 
In our study, we showed that patients with poor LVF who underwent CABG had a lower 8-
year mortality rate compared to patients who underwent PCI. This trend was consistent 
amongst several subgroups, including high-risk patients with triple-vessel CAD and urgent 
cases of revascularization. The study of Bangalore et al. [15] compared CABG versus PCI in 
the context of poor LVF using a propensity-analysis approach. They found no significant 
difference in gross mortality rates or within subgroups. Based on our study, it is not possible 
to delineate cardiac or non-cardiac related mortality rate between the 2 groups. Furthermore, 
MI, stroke and hospitalization for heart failure, especially in patients with poor LVF, were 
important outcomes that might lead to death. Bangalore et al. extended their investigation and 
evaluated several of these secondary outcomes. They found that patients who underwent PCI 
were twice as likely to suffer from MI following revascularization [16]. Incidence of MI 
directly correlates with an increased risk of death. Following this, it is not surprising that PCI 
patients have an increased risk of readmission, and in the majority of cases they require 
repeat revascularization [15, 16]. Taking primary and secondary outcomes from both papers 
into consideration, CABG remains a superior intervention for patients with poor LVF. Based 
on the SYNTAX II risk scoring system [17], a patient with 20% LVF scores 20.5 points 
higher if they receive PCI treatment instead of CABG treatment. Depending on the other 
variables, this can correlate with a 43.3% higher mortality. This reiterates the superiority of 
CABG to PCI in patients with poor LVF. It must be noted that LVF is just one aspect of a 
patient and by considering other factors, as the SYNTAX II model advocates, a clinician can 
deliver a more individualized level of care. Nevertheless, this scoring system showed that in 
the context of poor LVF, CABG yields a stronger survival function compared to PCI. 
The superiority of CABG over PCI can be explained by the dual function of CABG. In 
addition to providing revascularization, CABG improves LVF post-operatively. The average 
ejection fraction has been observed to increase from 25% to 31% as soon as 30 days 
following the operation [18]. This phenomenon was assessed more recently in both 
modalities. Revascularization by CABG and PCI increased LVEF by 15% and 5% after 
12 months, respectively [19]. Although PCI has the capacity to restore LVF, the magnitude of 
its effect is significantly lower [20]. With improved LVEF, patients will benefit from higher 
physical fitness levels and they are less likely to suffer the complications of heart failure. To 
reap these benefits, clinicians should implement viability testing in patients with poor LVF. 
Viability testing assesses the quality of the myocardial tissue and whether it is amenable to 
improved LVEF [12, 14]. Thus, patients with poor LVF and viable tissue would benefit from 
CABG to prevent further ischaemic damage and restore ventricular function. 
We found that CABG patients with poor LVF tend to require longer periods of recovery time 
in hospital following revascularization compared to PCI. This is not surprising as the 
operation is invasive, high-risk and demanding even in the simplest of cases. In contrast, 
major cardiology centres can sometimes perform PCI as day cases. Longer length of stay in 
hospital directly translates into more resources and costs consumed per CABG patient. In the 
ASCERT trial, CABG costs $10 670 and $8145 more than PCI per patient during the period 
of hospitalization (including the operation) and follow-up period, respectively [21]. However, 
when the analysis is extrapolated over a patient’s lifetime, CABG becomes substantially 
more economically attractive. The incremental cost-effectiveness ratio of CABG to PCI for 
patients with heart failure is $31 038/quality-adjusted life year (QALY) gained [22]. 
Interventions with an incremental cost-effectiveness ratio <$50 000/QALY gained are 
deemed favourable. This is primarily attributed to the fact that PCI patients experience higher 
rates of MI, readmission and repeat revascularization following the index revascularization—
all of which incur further costs to the healthcare institution. Additionally, 9 out of 10 papers 
in a systematic review report that CABG patients have a higher quality of life 1 year after 
revascularization compared to PCI patients [23]. In the context of a patient’s lifetime, 
performing CABG in patients with poor LVF is justifiable as the initial costs are offset by the 
long-term benefits experienced by the patient and the healthcare system. 
The technology used in PCI is rapidly evolving. Bare-metal stents have become obsolete, and 
second-generation DESs have proven dominance over first-generation DESs. Patient groups 
with second-generation DES unarguably enjoy lower rates of stent restenosis, stent 
thrombosis, repeat revascularization and death [6]. Other technologies such as GPIIa/IIIb 
inhibitors and peri-operative intra-aortic balloon pumps support PCI and offer significantly 
lower mortality rates compared to unsupported PCI [24]. They improve the ability and scope 
of PCI, allowing interventional cardiologists to treat high-risk patients, including those with 
poor LVF [25]. 
Limitations 
The overall quality of evidence presented is limited by the inherent biases that observational 
studies are susceptible to. One of them is the failure to control for pretreatment confounders 
and operator experience. Although in the original population the number of patients treated 
with CABG was larger than those treated with PCI, propensity matching was employed to 
address the issue of patients undergoing PCI due to surgical ineligibility. The matching 
process resulted in far fewer matches; i.e. 67 PCI cases were matched out of a potential 219. 
This may be due to the adherence of guidelines in the decision-making by the multi-
disciplinary team. Additionally, different data collection methods were employed by the 2 
registries, which may have resulted in inadequate reporting of patient and procedure 
characteristics. This could have resulted in less identical matches after propensity scoring and 
increases the influence of confounding bias. Although this study is based on 2 well-reputed 
national registries, they do not collect data on rehospitalization, rate of stroke, MI, repeat 
revascularization and life quality indices, and hence it is not possible to obtain these data 
based on our study. However, a well-designed RCT on this topic would indeed be able to 
address this issue. 
CONCLUSIONS 
Despite longer periods of hospitalization, this propensity-matched analysis has demonstrated 
that the CABG group has a significantly lower 8-year mortality rate compared to the PCI 
group in patients with poor LVF. In this context, we conclude that CABG is a superior 
revascularization intervention to the current standard of PCI. We believe that although 
guidelines are available to offer some advice on this, they are insufficient and based on weak 
evidence. This study will significantly contribute to the body of literature supporting the role 
of CABG in patients with poor LVF. However, in this modern era of interventional 
cardiology we are witnessing a diminishing difference in mortality rate between PCI and 
CABG. Above all, this topic merits the attention of an RCT in order to provide an irrefutable, 
truly unbiased answer that will enable clinicians to deliver the highest standard of healthcare 
to patients with poor LVEF. 
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